Cytokine Release Symptoms rather than Syndromes: A call for Granular Reporting of Cytokine Related Adverse Events in Clinical Trials
Résumé
Background: T-cell redirecting therapies, notably CAR T-cells and bispecific antibodies, have revolutionized the treatment of hematologic malignancies. Their rapid expansion into solid tumors, alongside the emergence of next-generation agents, such as immunocytokines and CD28-costimulatory bispecifics, has brought Cytokine Release Syndrome (CRS) to the forefront of clinical oncology. However, the absence of a unified grading system for these novel constructs remains a critical barrier to drug development and patient safety. Current toxicity management relies on disparate grading scales leading to inconsistent reporting and hindering cross-trial comparisons. A fundamental challenge lies in the diagnostic ambiguity created by the significant clinical and temporal overlap between CRS, infusion-related reactions (IRRs), and other diagnosis. While fever, hypotension, and hypoxia are common denominators, their distinct pathophysiological drivers necessitate divergent therapeutic interventions. Proposal: We advocate for a paradigm shift from aggregate syndromic grading toward a granular, longitudinal reporting framework. This approach prioritizes the precise documentation of symptom kinetics, specific interventions (e.g., exact vasopressor requirements, oxygen flow rates), and real-time biomarker integration By capturing high-fidelity data, researchers can retrospectively apply evolving criteria and develop more tailored, evidence-based management algorithms. Conclusion: Transitioning to a standardized, symptom-driven reporting model is essential to navigate the complexities of \"Immuno-oncology 2.0.\" Such a framework will harmonize safety assessments across global trials and ultimately optimize the therapeutic index of next-generation immunotherapies.